Impact of obstructive sleep apnea–hypopnea syndrome on coronary microcirculation in hypertensive patients Authors: Peipei Feng, Bo Wang, Xuekui Liu, Nan Lv, Tingting Zhou, Yueyue Feng, Ming Lou Published: 2026 ABSTRACT Objective:To investigate the impact of obstructive sleep apnea–hypopnea syndrome (OSAHS) on coronary microcirculatory function in hypertensive patients and explore potential mechanisms.Methods:A total of 87 patients underwent cardiac stress echocardiography, and 376 patients underwent angiography-derived microvascular resistance (AMR) assessment based on quantitative flow ratio (QFR) technology. All patients completed portable sleep monitoring. Based on the monitoring results and hypertension history, patients were categorized into five groups: control, hypertension alone, OSAHS alone, hypertension with mild OSAHS, and hypertension with moderate-to-severe OSAHS. Parameters including sleep monitoring data, coronary flow velocity reserve (CFVR), AMR, high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were compared among groups. Multivariable logistic regression analysis was performed to assess the influence of different groupings on coronary microvascular dysfunction.Results:The Hypertension with moderate-to-severe OSAHS group demonstrated significantly lower CFVR (P < 0.05) and significantly higher left anterior descending artery AMR (LAD-AMR), hs-CRP, and IL-6 levels compared to all other groups (P < 0.05). Multivariable logistic regression analysis revealed that, compared to the control group, hypertension with moderate-to-severe OSAHS was an independent correlate of both reduced CFVR [odds ratio (OR) = 6.06, 95% confidence interval (CI): 2.87–12.78] and elevated LAD-AMR (OR = 5.60, 95% CI: 4.10-7.10).Conclusion:In hypertensive patients, co-existing moderate-to-severe OSAHS is associated with more severe coronary microvascular dysfunction and elevated levels of inflammatory markers. INTRODUCTION Hypertension is a highly prevalent chronic disease worldwide, with the current number of patients exceeding 1.3 billion – approximately one-third of the global adult population. It is responsible for >10 million deaths annually, representing a substantial global disease burden [1]. Although hypertension manifests as elevated blood pressure in large arteries, its early stages are primarily characterized by microvascular impairment. Furthermore, damage to many target organs is centrally mediated by microvascular dysfunction and remodeling [2]. Obstructive sleep apnea–hypopnea syndrome (OSAHS) is a highly prevalent clinical sleep-related breathing disorder, closely associated with factors such as obesity, aging, and lifestyle. It is estimated that nearly 1 billion adults aged 30–69 worldwide have OSAHS, among whom 425 million have moderate to severe disease requiring treatment [3]. In China, the hypertensive population reaches 245 million, and approximately 30–50% of these individuals have comorbid OSAHS [4]. The core pathological feature of OSAHS is the recurrent partial or complete collapse of the upper airway during sleep, leading to airflow interruption. This, in turn, triggers chronic intermittent hypoxia, sleep fragmentation, and hypercapnia [5]. This unique pathophysiological state damages the microvasculature through multiple synergistic mechanisms: intermittent hypoxia activates oxidative stress, generating abundant reactive oxygen species that attack the vascular endothelium; the sustained release of inflammatory factors exacerbates vascular wall inflammation; and sympathetic overactivation coupled with autonomic nervous system dysfunction further disrupts microvascular regulatory capacity, ultimately leading to systemic microvascular injury [6]. Coronary microvascular dysfunction, an important cardiovascular risk factor independent of epicardial macrovascular disease, is closely linked to myocardial ischemia, heart failure and poor prognosis [7]. However, in hypertensive patients – who already have a baseline susceptibility to microcirculatory impairment – whether coexisting OSAHS further aggravates coronary microvascular dysfunction remains unclear. Previous studies have mainly focused on the impact of OSAHS on epicardial macrovessels or on blood pressure control in hypertensive patients. Although preliminary explorations have examined the association between OSAHS and coronary microcirculation, existing studies have notable limitations. First, most studies have analyzed the overall OSAHS patient population without adequately stratifying the effects of OSAHS severity on coronary microcirculation. Second, hypertension is one of the most common comorbidities of OSAHS; the interactive or additive effects of hypertension and different severities of OSAHS on coronary microcirculation remain poorly defined. Therefore, this study aims to evaluate coronary microvascular function using coronary flow velocity reserve (CFVR) and angiography-derived microvascular resistance (AMR), and to measure inflammatory markers including high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6), to explore the impact of OSAHS on coronary microcirculatory function in hypertensive patients and the underlying inflammatory mechanisms. The findings may provide evidence for early identification of high-risk patients and for multidimensional clinical intervention. MATERIALS AND METHODS Study population This was a single-center, observational, cross-sectional study. A total of 428 patients admitted to the Department of Cardiology, Xuzhou Central Hospital, China, between September 2024 and October 2025 were enrolled, including 271 patients with hypertension and 157 patients without hypertension. All patients underwent stress echocardiography or AMR assessment based on quantitative flow ratio (QFR) technology, and 35 patients completed both examinations. The study consisted of two parts. In Part 1, to assess coronary microcirculatory function, 87 patients who met the indications for stress echocardiography and had no relevant contraindications underwent the examination, providing coronary flow velocity reserve (CFVR) data. In Part 2, to complement the assessment and expand the sample size, an additional 376 hypertensive patients who underwent invasive coronary angiography for clinically suspected coronary artery disease received simultaneous angiography-derived microvascular resistance (AMR) assessment based on QFR technology. All patients were enrolled according to uniform inclusion and exclusion criteria. This study was approved by the Biomedical Research Ethics Committee of Xuzhou Central Hospital (Approval No. XZXY-LK-20240920-0148) and was registered with the Chinese Clinical Trial Registry (Registration No. ChiCTR2500107966). Written informed consent was obtained from all participants prior to their enrollment. Diagnostic criteria Diagnostic criteria for hypertension Hypertension was defined according to the 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension[8]. The diagnostic criteria included any of the following: seated office blood pressure measurements ≥140/90 mmHg on at least two different occasions in the absence of antihypertensive medication; or an average home blood pressure ≥135/85 mmHg based on repeated measurements; or 24-h ambulatory blood pressure monitoring showing an average blood pressure ≥130/80 mmHg, with daytime average ≥ 135/85 mmHg and nighttime average ≥120/70 mmHg. Additionally, patients with a documented history of hypertension who were currently receiving antihypertensive medication were also diagnosed with hypertension. Diagnostic criteria for OSAHS The diagnosis of OSAHS was established with reference to the screening recommendations of the U.S. Preventive Services Task Force (USPSTF) and the clinical practice standards of the American Academy of Sleep Medicine (AASM) [9]. OSAHS was confirmed when either of the following criteria was met: the presence of typical obstructive sleep apnea symptoms (e.g., snoring, daytime sleepiness, witnessed apnea) accompanied by an apnea-hypopnea index (AHI) ≥ 5 events/h with predominantly obstructive events, as documented by polysomnography (PSG) or validated portable sleep monitoring; or an AHI ≥ 15 events/hour on PSG or portable sleep monitoring, even in the absence of symptoms. Disease severity was graded as follows: mild OSAHS (5 ≤ AHI < 15 events/h), moderate OSAHS (15 ≤ AHI ≤ 30 events/h), and severe OSAHS (AHI > 30 events/h). Inclusion and exclusion criteria Participants were enrolled if they met the following criteria: diagnosis of hypertension according to the 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension; age 18-75 years; completion of >5 h of portable sleep monitoring; underwent either stress echocardiography or QFR-based AMR assessment during hospitalization; and provided written informed consent. Patients were excluded for any of the following: secondary hypertension other than OSAHS-related hypertension; type I or II diabetes mellitus; >50% stenosis in epicardial coronary arteries on angiography or CTA; contraindications to stress echocardiography (e.g., sick sinus syndrome, second-degree or higher atrioventricular block without a pacemaker, acute asthma attack, severe hypotension) or allergy to pharmacological agents used during stress echocardiography; poor angiographic image quality unsuitable for QFR-AMR analysis; severe comorbidities (e.g., malignancy, organ failure, severe cerebral or digestive system disease); concurrent rheumatic immune system disease or hematological disease; active infection within 4 weeks; poor compliance as judged by the investigator. Data collection and grouping Clinical data were systematically collected for all participants. This included demographic characteristics (age, sex), body mass index (BMI), and biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), uric acid (UA), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Data related to hypertension comprised the first blood pressure measurement during hospitalization, duration of hypertension, grade of hypertension, and history of antihypertensive medication use. Inflammatory markers assessed were hs-CRP and IL-6. Coronary microvascular function was evaluated using CFVR and AMR. Portable sleep monitoring was performed using a Wanmai Polysomnography Monitor (Model SF-A9; Hunan Wanmai Medical Technology Co., Ltd, China). The recorded parameters included apnea-hypopnea index (AHI), minimum oxygen saturation (MinSpO2), mean oxygen saturation (MeanSpO2), oxygen desaturation index (ODI), apnea index (AI), and hypopnea index (HI). Portable monitoring (PM) is recognized by the American Academy of Sleep Medicine as a valid method for diagnosing OSAHS, demonstrating good correlation with in-laboratory polysomnography [10] Furthermore, The American Academy of Sleep Medicine (AASM), in its 2017 publication “Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline” [9] recommended the use of portable monitors (PMs) as a first-line diagnostic tool for adults with suspected uncomplicated moderate to severe OSA. Based on the AHI results and hypertension status, participants were stratified into five distinct groups: control group (no prior history of hypertension and OSAHS excluded by portable sleep monitoring; these patients were admitted with clinically suspected coronary artery disease symptoms), hypertension-only group, OSAHS-only group, hypertension with mild OSAHS group, and hypertension with moderate-to-severe OSAHS group. Instrumentation and measurement protocols Stress echocardiography CFVR was assessed using a color Doppler ultrasound system (Philips Ultrasound Inc., model EPIQ 7C) equipped with an S5-1 phased array transducer (frequency range: 1–5 MHz). With the patient in the left lateral decubitus position, the distal segment of the left anterior descending coronary artery was identified in the fourth or fifth intercostal space near the midclavicular line using coronary flow imaging mode. The baseline diastolic coronary flow velocity was recorded at rest. A 0.4 mg dose of regadenoson diluted in 5 ml of solution was then administered as an intravenous bolus via the left antecubital vein over 10 s, followed by a 5 ml saline flush, to induce maximal coronary hyperemia. The peak diastolic flow velocity was recorded during hyperemia. CFVR was calculated as the ratio of hyperemic to resting diastolic coronary flow velocities. Coronary microvascular function was assessed by measuring CFVR using stress echocardiography. This method was employed in accordance with the recommendations outlined in the clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) [11], All examination results were jointly verified by two sonographers with associate senior professional titles. AMR measurement AMR was assessed using the Angioplus QFR measurement system (Model: QFR-2.0; Pulse Medical Imaging Technology, Shanghai, China). QFR technology has received a Class I recommendation for the functional assessment of coronary artery disease in the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes[12]. Statistical analysis Statistical analyses were performed using R software version 4.5.2. Continuous variables with a normal distribution were expressed as mean ± standard deviation (x ± s). Comparisons among multiple groups were conducted using one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) test for pairwise comparisons. Continuous variables with a nonnormal distribution were expressed as median (P25, P75) [M(P25, P75)] and compared among groups using the nonparametric Kruskal–Wallallis H test. When a statistically significant difference was detected (P < 0.05), pairwise comparisons were performed using the Mann–Whitney U test, with P-values adjusted by the Bonferroni method. Categorical variables were presented as counts (percentages) and compared using the chi-square test or Fisher's exact test, as appropriate. Multivariable logistic regression analysis was used to assess the impact of different groupings on coronary microvascular dysfunction, with results expressed as odds ratios (OR) and 95% confidence intervals (95% CI). The regression model was adjusted for sex, age, BMI, neck circumference, hemoglobin, IL-6. A two-sided P-value <0.05 was considered statistically significant. RESULTS Study design This study enrolled two independent patient cohorts to evaluate coronary microvascular function in patients with hypertension (HTN) combined with different severities of OSAHS (Fig. 1). In the SE cohort (Fig. 1a), a total of 87 participants were enrolled and divided into five groups: control group (n = 19), hypertension alone group (n = 14), OSAHS alone group (n = 15), hypertension with mild OSAHS group (n = 18), and hypertension with moderate-to-severe OSAHS group (n = 21). CFVR, a noninvasive index of coronary microvascular function, was measured by SE. In the QFR cohort (Fig. 1b), a total of 376 patients were enrolled and divided into the same five groups: control group (n = 71), hypertension group (n = 60), OSAHS group (n = 81), hypertension with mild OSAHS group (n = 71), and hypertension with moderate-to-severe OSAHS group (n = 93). AMR of the left anterior descending artery (LAD) was calculated based on QFR technology. As shown in Fig. 1, both CFVR and LAD-AMR differed significantly among the groups (Kruskal–Wallis test, P = 1.2 × 10−5, and P = 2.26 × 10−16, respectively). Among hypertensive patients with OSAHS, CFVR progressively decreased, while LAD-AMR progressively increased with increasing severity of OSAHS. Study design. Comparison of baseline clinical characteristics Significant differences among the five groups were observed in LAD-AMR, hs-CRP grade, IL-6, BMI, neck circumference, and hemoglobin levels (P < 0.05). No significant differences were found in other baseline characteristics, including gender, smoking history, fasting blood glucose, duration of hypertension, usual clinic systolic and diastolic blood pressure, and antihypertensive medication use (P < 0.05), as detailed in Table 1. TABLE 1Comparison of baseline clinical characteristicsPanel AComparison of baseline clinical characteristics in 87 patients who underwent CFVR measurementControl (N = 19)Hypertension alone (N = 14)OSAHS alone (N = 15)Hypertension + mild OSAHS (N = 18)Hypertension + moderate–severe OSAHS (N = 21)P valueAge (years)54.42 ± 7.3061.07 ± 7.5255.80 ± 10.7461.33 ± 10.0256.14 ± 12.870.150Sex (male/female)8/115/98/76/1215/60.117Neck circumference (cm)36.92 ± 2.7638.04 ± 1.7140.20 ± 2.98a,b,d38.03 ± 3.6140.43 ± 2.44a,b,d<0.001BMI (kg/m2)23.89 ± 3.3024.36 ± 2.5128.74 ± 6.84a,b26.10 ± 4.3628.14 ± 3.72a,b0.003Smoking history, n (%)5 (26.3)3 (21.4)4 (26.7)3 (16.7)8 (38.1)0.651Fasting blood glucose (mmol/l)4.57 ± 0.745.03 ± 0.784.96 ± 1.074.84 ± 0.524.51 ± 0.600.163TC (mmol/l)4.34 ± 1.134.25 ± 1.383.94 ± 1.124.63 ± 1.134.25 ± 0.950.540TG (mmol/l)1.42 ± 0.821.30 ± 0.781.33 ± 0.821.78 ± 1.061.55 ± 1.010.545LDL-C (mmol/l)2.35 ± 0.672.36 ± 1.032.12 ± 0.732.53 ± 0.862.40 ± 0.730.678Hemoglobin (g/l)132.32 ± 13.77126.21 ± 17.34140.53 ± 12.78b136.83 ± 13.76b141.95 ± 15.74a,b0.021LVEDD (mm)46.63 ± 2.9147.57 ± 3.4646.60 ± 3.2046.50 ± 3.6249.62 ± 5.040.056LVEF (%)59.84 ± 1.7758.71 ± 1.7760.27 ± 1.4958.28 ± 2.3258.38 ± 5.690.269Statin use, n (%)13 (68.4)8 (57.1)8 (53.3)14 (77.8)15 (71.4)0.573hs-CRP levels0.008Grade 1 (%)18 (32.7)9 (16.4)8 (14.5)11 (20.0)9 (16.4)Grade 2 (%)1 (4.2)4 (16.7)7 (29.2)6 (25.0)6 (25.0)Grade 3 (%)0 (0.0)1 (12.5)0 (0.0)1 (12.5)6 (75.0)aIL-6 (pg/ml)2.37 ± 0.513.07 ± 0.62a2.88 ± 0.67a3.12 ± 0.64a3.84 ± 0.81a,b,c,d<0.001Antihypertensive medicationsBeta-blocker, n (%)5 (35.7)6 (33.3)8 (38.1)0.953*ACEI/ARB/ARNI, n (%)4 (28.6)8 (44.4)5 (23.8)0.368*Calcium channel blocker, n (%)3 (21.4)9 (50.0)9 (42.9)0.242*Hypertension profileDuration of hypertension (years)6 (2.75,10.0)5.5 (2.75,10.0)10 (3.5,17.5)0.725*Usual office SBP (mmHg)132.8 ± 13.43140.89 ± 17.02144.81 ± 19.200.134*Usual office DBP (mmHg)83.29 ± 10.9186.00 ± 14.8791.52 ± 16.650.244*Panel BComparison of baseline clinical characteristics in 376 patients who underwent AMR measurementControl (N = 71)Hypertension alone (N = 60)OSAHS alone (N = 81)Hypertension + mild OSAHS (N = 71)Hypertension + moderate–severe OSAHS (N = 93)P valueAge (years)57.54 ± 10.4662.07 ± 7.9159.51 ± 11.1360.99 ± 12.1257.86 ± 11.350.059Sex (male/female)38/3332/2842/3936/3561/320.271Neck Circumference (cm)36.91 ± 1.5837.10 ± 1.8638.23 ± 2.6839.16 ± 2.80a40.12 ± 2.35a,b,c,d<0.001BMI (kg/m2)24.10 ± 2.9024.66 ± 3.4425.24 ± 4.1626.68 ± 4.37a,b,c28.17 ± 3.66a,b,c,d<0.001Smoking history, n (%)27 (38.0)18 (30.0)27 (33.3)27 (38.0)45 (48.4)0.158Fasting blood glucose (mmol/l)5.03 ± 0.825.01 ± 0.675.06 ± 1.065.40 ± 1.185.08 ± 0.670.157TC (mmol/l)3.91 ± 1.023.78 ± 0.834.07 ± 1.094.07 ± 1.024.09 ± 0.920.299TG (mmol/l)1.36 ± 0.651.61 ± 0.651.45 ± 0.941.65 ± 0.901.67 ± 0.820.078LDL-C (mmol/l)2.16 ± 0.822.14 ± 0.682.25 ± 0.812.38 ± 0.832.39 ± 0.730.166Hemoglobin (g/l)133.97 ± 14.13130.48 ± 14.87135.05 ± 19.73b138.79 ± 15.66b142.97 ± 12.20a,b,c<0.001LVEDD (mm)47.16 ± 4.4248.50 ± 4.7547.90±4.9646.79 ± 6.7648.74 ± 5.700.129LVEF (%)58.35±4.5859.05 ± 4.2658.81 ± 5.7158.95 ± 4.3658.94 ± 7.450.954Statin use, n (%)60 (84.5)50 (83.3)73 (90.1)65 (91.5)87 (26.0)0.198LCX-AMR (mmHg s/cm)2.53 ± 0.282.85 ± 0.32a2.92 ± 0.37a2.90 ± 0.32a3.17 ± 0.44a,b,c,d<0.001RCA-AMR (mmHg s/cm)2.60 ± 0.372.73 ± 0.392.70 ± 0.482.72 ± 0.412.80 ± 0.560.190hs-CRP levels0.007Grade 161 (29.2)32 (15.3)49 (23.4)43 (20.6)24 (11.5)Grade 210 (8.9)27 (24.1)21 (18.8)19 (17.0)35 (31.3)Grade 30 (0)1 (1.8)a11 (20.0)a9 (16.4)a34 (61.8)a,b,c,dIL-6 (pg/ml)2.62 ± 0.793.45 ± 0.83a3.56 ± 0.91a3.54 ± 0.80 a4.30 ± 0.69a,b,c,d<0.001Antihypertensive medicationsBeta-blocker, n (%)26 (43.3)37 (52.1)46 (49.5)0.593*ACEI/ARB/ARNI, n (%)25 (41.7)32 (45.1)45 (48.4)0.714*Calcium channel blocker, n (%)23 (38.3)37 (52.1)52 (55.9)0.096*Hypertension profileDuration of hypertension (years)6.0 (3.0,10.0)8.0 (5.0,10.0)7.0 (2.5,10.0)0.935*Usual office SBP (mmHg)138.95 ± 15.02139.41 ± 22.22133.71 ± 15.810.079*Usual office DBP (mmHg)82.42±10.1283.62±13.9481.58±12.580.583*ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LCX, left circumflex artery; LDL-C, low density lipoprotein; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; OSAHS, obstructive sleep apnea–hypopnea syndrome; RCA, right coronary artery; Statistical significance (P < 0.05) in pairwise comparisons is indicated by superscript letters, TC, total cholesterol; TG, triglyceride.avs. control group.bvs. hypertension alone group.cvs. OSAHS alone group.dvs. hypertension with mild OSAHS group.*Comparisons across the three groups: hypertension alone, hypertension with mild OSAHS, and hypertension with moderate-to-severe OSAHS. hs-CRP levels were categorized per AHA/CDC guidelines as Grade 1 (low risk: <1.0 mg/l), Grade 2 (intermediate risk: 1.0–3.0 mg/l), or Grade 3 (high risk: >3.0 mg/l). Data were presented as mean ± SD, median and quartiles, and proportions. Comparison of baseline clinical characteristics ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LCX, left circumflex artery; LDL-C, low density lipoprotein; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; OSAHS, obstructive sleep apnea–hypopnea syndrome; RCA, right coronary artery; Statistical significance (P < 0.05) in pairwise comparisons is indicated by superscript letters, TC, total cholesterol; TG, triglyceride. vs. control group. vs. hypertension alone group. vs. OSAHS alone group. vs. hypertension with mild OSAHS group. Comparisons across the three groups: hypertension alone, hypertension with mild OSAHS, and hypertension with moderate-to-severe OSAHS. hs-CRP levels were categorized per AHA/CDC guidelines as Grade 1 (low risk: <1.0 mg/l), Grade 2 (intermediate risk: 1.0–3.0 mg/l), or Grade 3 (high risk: >3.0 mg/l). Data were presented as mean ± SD, median and quartiles, and proportions. Comparison of CFVR and LAD-AMR levels Significant differences in CFVR were observed among the five groups (P < 0.05). The CFVR in the hypertension with moderate-to-severe OSAHS group was significantly lower than that in all other groups (P < 0.05). No statistically significant difference in CFVR was found between the hypertension with mild OSAHS group and the hypertension alone group or the OSAHS alone group (P > 0.05) (Fig. 2, panel a). Comparison of CFVR and LAD-AMR levels among five patient groups. (a) Forest plot showing adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for coronary microvascular dysfunction (CMVD, defined as CFVR ≤ 2.50 per the 2023 Chinese Expert Consensus on the Diagnosis and Treatment of Coronary Microvascular Disease) across study groups, with the control group as the reference. (b) Forest plot illustrating adjusted ORs and 95% CIs for CMVD (defined as LAD-AMR ≥ 2.51 mmHg s/cm, per validated correlations with invasive index of microcirculatory resistance) across the same groups. All analyses were adjusted for sex, age, body mass index (BMI), neck circumference, hemoglobin, and interleukin-6 (IL-6). The dotted vertical line at OR = 1.0 represents the null effect. Significant differences in LAD-AMR were observed among the five groups (P < 0.05). The LAD-AMR in the hypertension with moderate-to-severe OSAHS group was significantly higher than that in all other groups (P < 0.05). In contrast, no statistically significant difference in these parameters was found between the hypertension with mild OSAHS group and the hypertension alone group or the OSAHS alone group (P > 0.05) (Fig. 2, panel b). Multivariable logistic regression analysis of factors influencing CFVR and LAD-AMR According to Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition)[13], CFVR ≤2.50 indicates coronary microvascular dysfunction. In the multivariable logistic regression analysis after adjusting for the prespecified covariates and using the control group as reference, the risk of microvascular dysfunction was 3.18 times higher (OR = 3.18, 95% CI: 1.65–5.64) in the Hypertension with mild OSAHS group and 6.06 times higher (OR = 6.06, 95% CI: 2.87–9.23) in the Hypertension with moderate-to-severe OSAHS group. These results indicate that hypertensive patients with co-existing moderate-to-severe OSAHS have a substantially higher risk of developing coronary microvascular dysfunction (Fig. 3, panel a). Multivariate logistic regression analysis of factors influencing CFVR and LAD-AMR. (a) Forest plot showing adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for coronary microvascular dysfunction (CMVD, defined as CFVR ≤ 2.50 per the 2023 Chinese Expert Consensus on the Diagnosis and Treatment of Coronary Microvascular Disease) across study groups, with the control group as the reference. (b) Forest plot illustrating adjusted ORs and 95% CIs for CMVD (defined as LAD-AMR ≥ 2.51 mmHg s/cm, per validated correlations with invasive index of microcirculatory resistance) across the same groups. All analyses were adjusted for sex, age, body mass index (BMI), neck circumference, hemoglobin, and interleukin-6 (IL-6). The dotted vertical line at OR = 1.0 represents the null effect. Previous studies have established a strong correlation between AMR and the invasive index of microcirculatory resistance (IMR) [14,15]. An LAD-AMR ≥2.51 mmHg s/cm was used to define coronary microvascular dysfunction [16]. After adjusting for the prespecified covariates and using the control group as reference, the risk of microvascular dysfunction was 3.34 times higher (OR = 3.34, 95% CI: 2.18–4.51) in the hypertension with mild OSAHS group and 5.60 times higher (OR = 5.60, 95% CI: 4.10–7.10) in the hypertension with moderate-to-severe OSAHS group. This confirms a markedly elevated risk in hypertensive patients with moderate-to-severe OSAHS (Fig. 3, panel b). Correlation analysis between CFVR and LAD-AMR Pearson correlation analysis showed a negative correlation between CFVR and LAD-AMR (r = −0.797, P < 0.001), as detailed in Fig. 4. To further validate this correlation at the individual participant level, we provide Figure 1, Supplemental Digital Content, which presents paired CFVR (blue dots) and LAD-AMR (red dots) values for the 35 patients who completed both examinations (arranged along the horizontal axis by patient serial number). Figure 1, Supplemental Digital Content demonstrates an obvious inverse trend between CFVR and LAD-AMR at the individual patient level, consistent with the strong negative correlation shown in Fig. 4. This further confirms that the inverse association between CFVR and LAD-AMR is a robust feature of the study population and is not driven by a small number of outliers. Correlation between CFVR and LAD-AMR. DISCUSSION Hypertension represents a primary risk factor for cardiovascular disease and poses a significant threat to global health [17]. In China, the population with hypertension comorbid with OSAHS is estimated to reach approximately 70 million [4]. Previous research on hypertensive patients with OSAHS has predominantly focused on mechanisms underlying poor blood pressure control, elucidating pathways such as sympathetic overactivation, renin-angiotensin-aldosterone system activation leading to sodium retention, vascular endothelial injury, chronic inflammatory responses, and disrupted circadian blood pressure rhythms induced by OSAHS [18]. To the best of our knowledge, no prior studies have specifically investigated whether OSAHS exacerbates coronary microcirculatory dysfunction. The present study revealed that hypertensive patients with moderate-to-severe OSAHS exhibit more pronounced coronary microvascular dysfunction, characterized by significantly reduced CFVR and notably elevated LAD-AMR values. The underlying mechanism may be attributed to the chronic intermittent hypoxia and nocturnal arousals induced by moderate-to-severe OSAHS, which activate oxidative stress and systemic inflammation, leading to the release of abundant reactive oxygen species and inflammatory factors. These processes directly damage the vascular endothelium, reduce nitric oxide bioavailability, and ultimately impair vasodilatory function [19]. Concurrently, hypoxia and hypercapnia persistently stimulate the sympathetic nervous system, resulting in nocturnal hypertension, sustained vasoconstriction, and vascular remodeling, which further aggravate microcirculatory impairment [20]. These findings align with observations by Yoshitaka et al. in a population with acute myocardial infarction [21]. Multivariate logistic regression analysis in our study demonstrated that, using a CFVR ≤2.5 as the diagnostic threshold for coronary microvascular dysfunction, patients with hypertension and moderate-to-severe OSAHS had a 6.06-fold increased risk compared to the control group. Similarly, using an LAD-AMR ≥2.51 mmHg s/cm as the criterion, the risk was 5.60 times higher. These results strongly suggest that concomitant moderate-to-severe OSAHS substantially increases the risk of coronary microvascular dysfunction in hypertensive patients. Furthermore, our study found no statistically significant differences in CFVR or AMR values between the hypertension with mild OSAHS group and either the hypertension-only or OSAHS-only groups. This indicates that the detrimental effect of OSAHS on the coronary microcirculation in hypertensive patients is not an “all-or-nothing” phenomenon, but rather follows a dose-response relationship with disease severity. A synergistic amplification effect may exist between the hemodynamic stress of hypertension and the intermittent hypoxia of OSAHS, collectively imposing a “1+1 > 2” detrimental impact on the coronary microvasculature. While mild OSAHS also involves intermittent hypoxia and sleep fragmentation, its frequency and depth of desaturation may not reach the threshold required to induce detectable significant changes in coronary microvascular function [22]. The progression of microvascular endothelial dysfunction and structural remodeling is gradual. The pathological stimulus intensity provided by mild OSAHS might be insufficient to produce an additional synergistic worsening effect atop the preexisting microvascular injury associated with hypertension. To more comprehensively assess microcirculatory function, this study combined CFVR and AMR. The results showed that in hypertensive patients with moderate-to-severe OSAHS, AMR values in both the left anterior descending artery and the left circumflex artery were significantly higher than those in the hypertension alone group and the mild OSAHS group, consistent with the decreasing trend in CFVR. This finding has multiple implications. First, using a separate independent cohort, it confirms, through three-dimensional reconstruction and hemodynamic analysis after coronary angiography, an association between OSAHS severity and increased coronary microcirculatory resistance. Elevated AMR directly reflects increased resistance to blood flow at the microvascular level, suggesting microvascular structural remodeling or dysfunction, which is consistent with the notion that OSAHS not only induces microvascular functional impairment but may also promote structural abnormalities [23]. Second, analysis of patients who completed both examinations revealed a significant negative correlation between CFVR and LAD-AMR. This indicates that the decline in flow reserve capacity reflected by CFVR and the increase in microvascular resistance represented by AMR are consistently linked at the individual level, reinforcing that the two metrics capture different dimensions of the same pathophysiological process of coronary microvascular dysfunction. This also supports the physiological rationale and complementarity of combining both indicators in the present study. Notably, AMR values in the right coronary artery did not differ significantly among groups. This may be related to differences in the myocardial territory supplied, the impact of cyclic mechanical stress induced by intrathoracic pressure fluctuations, anatomical characteristics, and sensitivity to pathological stimuli compared with the left coronary system [24,25]. The left anterior descending artery is a direct continuation of the left coronary artery and supplies blood to the anterior wall of the left ventricle, the apex, the anterior two-thirds of the interventricular septum, and part of the anterior wall of the right ventricle. Compared with the left circumflex artery and the right coronary artery, microvascular dysfunction in the LAD territory is more likely to predispose to myocardial ischemia and adverse prognosis [26]. Therefore, LAD-AMR may serve as a sensitive and comprehensive indicator reflecting the overall status and reserve capacity of the coronary microcirculation, which is consistent with the findings of Qiu et al.[27]. Our study found that patients with hypertension and concomitant moderate-to-severe OSAHS exhibited significantly elevated levels of the inflammatory markers IL-6 and hs-CRP grades. This suggests that inflammatory responses may be involved in the mechanism by which OSAHS exacerbates coronary microcirculatory impairment in hypertensive patients. Intermittent hypoxia can activate inflammatory pathways, such as NF-κB, promoting the release of IL-6 and hs-CRP, which directly damage vascular endothelial function and consequently affect the coronary microcirculation [28]. In contrast, patients with hypertension and mild OSAHS showed no significant increase in IL-6 and hs-CRP grades compared to those with hypertension alone or OSAHS alone. This aligns with the CFVR and AMR findings, indicating that mild OSAHS may not yet trigger a significant systemic inflammatory response, and further supporting inflammation as a key link connecting OSAHS to microcirculatory dysfunction [29]. This study possesses certain clinical innovations. Firstly, while existing research has predominantly focused on the impact of OSAHS on elevating blood pressure levels in hypertensive patients, our study further investigates the damage inflicted by OSAHS on the coronary microcirculation–a target organ insufficiently emphasized in this population. This provides a potential mechanistic explanation for the clinical consensus that “OSAHS increases the risk of cardiovascular events in hypertensive patients,” namely through the impairment of the coronary microcirculation. Secondly, we incorporated the measurement of inflammatory biomarkers, aiming to explore the potential pathway – specifically, the inflammatory response – through which OSAHS affects the coronary microcirculation in hypertensive patients. Several limitations of this study should be acknowledged. First, its cross-sectional design precludes the establishment of causal relationships. Second, the stress echocardiography protocol currently employed primarily assesses blood flow reserve in the territory supplied by the left anterior descending artery. Furthermore, this technique is operator-dependent, and image quality can be compromised by patient body habitus or lung interference. Third, the relatively small sample size may limit the robust statistical power of our findings. Future prospective cohort studies are warranted to validate the causal relationship between OSAHS and coronary microvascular dysfunction in hypertensive patients and to investigate its long-term effects on the coronary microcirculation. In conclusion, this study demonstrates that the detrimental effect of OSAHS on coronary microcirculatory function in hypertensive patients is markedly severity–dependent. Moderate-to-severe OSAHS significantly impairs coronary microvascular function, whereas the deleterious effect of mild OSAHS is comparatively limited. The underlying mechanism is closely associated with systemic chronic inflammation triggered by OSAHS. These findings highlight the clinical importance of severity–stratified assessment of OSAHS in patients with hypertension: for those with coexisting moderate-to-severe OSAHS, routine screening for coronary microvascular dysfunction and active intervention for OSAHS are recommended; for those with mild OSAHS, clinical decisions should integrate individual hypoxic exposure and other risk factors. ACKNOWLEDGEMENTS Ming Lou are senior and corresponding authors. Ming Lou have full access to all the data in this study and take full responsibility as guarantors for the integrity of the data and the accuracy of the data analysis. Ming Lou contributed to study design and final approval of the manuscript. Peipei Feng contributed to studies collection, data extraction, data analysis, data interpretation, and manuscript drafting. Bo Wang contributed to contributed to studies collection and data extraction. Xuekui Liu contributed to data analyses and interpretation with support from Nan Lv and Tingting Zhou and Yueyue Feng. The corresponding author attests that all listed authors meet authorship criteria, that no others meeting the criteria have been omitted and that written authorization has been received from all co-authors and contributors. Funding: The author (Ming Lou) gratefully acknowledges the support of the “333 Project” of Jiangsu Province (CN), Project Number: BRA2020250. Conflicts of interest The authors declare that they have no competing interests or any other interests that might be perceived to influence the results and discussion reported in this paper. Supplementary Material Supplemental Digital Content